The University of Texas Health Science Center at Houston, Houston, TX, USA.
Center for Cardiovascular Disease Prevention, Baylor Scott and White Health Heart Hospital Baylor Plano, Plano, TX, USA.
Curr Cardiol Rep. 2023 Sep;25(9):969-978. doi: 10.1007/s11886-023-01911-9. Epub 2023 Jul 5.
To provide an updated review of bempedoic acid's clinical application in lowering LDL-C in the setting of statin intolerance and the recent findings in the CLEAR Outcomes trial as well as summarize and synthesize the current state of knowledge regarding bempedoic acid while providing an in-depth analysis of the drug's pharmacological properties, mechanism of action, clinical trials, safety, and efficacy.
The CLEAR Outcomes trial has provided evidence to support bempedoic acid as a viable alternative to statins for the primary and secondary prevention of cardiovascular disease. Bempedoic acid is a promising treatment option for patients with hypercholesterolemia who are unable to tolerate statin therapy or require additional LDL-C reduction in the treatment of cardiovascular disease, with the newest lipid-lowering cardiovascular outcomes trials expanding on their generalizability particularly in the inclusion of women.
提供贝匹地酸在他汀不耐受情况下降低 LDL-C 的临床应用的最新综述，以及最近 CLEAR Outcomes 试验的结果，总结和综合贝匹地酸的现有知识，同时深入分析药物的药理学特性、作用机制、临床试验、安全性和疗效。
CLEAR Outcomes 试验为贝匹地酸作为他汀类药物的替代品，用于心血管疾病的一级和二级预防提供了证据。对于不能耐受他汀类药物治疗或需要在心血管疾病治疗中进一步降低 LDL-C 的高胆固醇血症患者，贝匹地酸是一种很有前途的治疗选择，最新的降脂心血管结局试验扩大了其普遍性，特别是在纳入女性方面。
